| Metric | Value ($ M) |
|---|---|
| Revenue | 20.00 |
| Total Income | 20.00 |
| Expenditure | 44.22 |
| PBT | — |
| Net Profit | -19.86 |
| OPM | — |
| NPM | -99.28% |
| EPS | -0.42 |
Rapport Therapeutics Reports Q1 2026 Financials, Provides Business Update
07 May 2026 · 7 May, 4:47 pm
Summary
Rapport Therapeutics reported its financial results for the quarter ended March 31, 2026. The company's net loss for the quarter was $19.9 million, compared to $24.1 million for the same period last year. Collaboration revenues for the quarter were $20.0 million due to the Tenacia License Agreement. The company ended the quarter with $476.8 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029.
Key Highlights
- 1
Rapport Therapeutics reported first quarter 2026 financial results, ending March 31, 2026.
- 2
The company ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments.
- 3
Collaboration revenues were $20.0 million for the first quarter of 2026 due to the Tenacia License Agreement.
- 4
Net loss for the first quarter of 2026 was $19.9 million, compared to $24.1 million for the prior year period.
- 5
R&D expense was $32.7 million for the first quarter of 2026, as compared to $19.6 million for the prior year period.
- 6
The Phase 3 program in FOS remains on track for initiation in the second quarter of 2026.
- 7
RAP-219 Phase 2 trial in bipolar mania topline results are now expected in the fourth quarter of 2026.
Management Comments
Abraham N. Ceesay
“We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219’s treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials." “With multiple important development milestones ahead, including continued advancement of our epilepsy franchise, progress in bipolar mania, and development of our long-acting injectable formulation, we believe we are well positioned to continue building value across our pipeline.”
Informational and educational content only. Not investment advice.